Biocardia Inc. painted a largely upbeat picture for the second quarter of 2019, despite tallying a net loss of $3.8 million, up from $3.2 million in the same period a year ago. Among the quarter's highlights were U.S. FDA clearance to market the Advance steerable introducer for cardiac catheter procedures and expansion of the phase III CardiAMP Heart Failure Trial.